Orchestra BioMed Holdings, Inc. (OBIO)
| Market Cap | 550.93M +130.7% |
| Revenue (ttm) | 31.21M +1,007.4% |
| Net Income | -58.36M |
| EPS | -0.92 |
| Shares Out | 78.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 479,793 |
| Open | 7.50 |
| Previous Close | 7.46 |
| Day's Range | 6.96 - 7.63 |
| 52-Week Range | 3.46 - 7.83 |
| Beta | 0.55 |
| Analysts | Strong Buy |
| Price Target | 13.29 (+89.86%) |
| Earnings Date | Nov 10, 2026 |
About OBIO
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company’s flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a b... [Read more]
Financial Performance
In 2025, Orchestra BioMed Holdings's revenue was $33.48 million, an increase of 1169.22% compared to the previous year's $2.64 million. Losses were -$52.96 million, -13.22% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for OBIO stock is "Strong Buy." The 12-month stock price target is $13.29, which is an increase of 89.86% from the latest price.
News
Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference
NEW HOPE, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technolo...
Orchestra BioMed price target raised to $12 from $10 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Orchestra BioMed (OBIO) to $12 from $10 and keeps a Buy rating on the shares following the research and development day. Orchestra…
Orchestra BioMed price target raised to $12 from $10 at BTIG
BTIG analyst Marie Thibault raised the firm’s price target on Orchestra BioMed (OBIO) to $12 from $10 and keeps a Buy rating on the shares. Following the company’s R&D Day,…
Orchestra BioMed Holdings Transcript: R&D Day 2026
BACKBEAT enrollment is complete, with primary results expected in early 2027. Virtue’s 740-patient pivotal trial is enrolling, while funding through 2028 and Medtronic collaboration support development and potential commercialization.
Orchestra BioMed reports Q3 EPS (30c), consensus (40c)
Reports Q3 revenue $91k, consensus $103.5k. David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed (OBIO), stated, “With the completion of enrollment of the BACKBEAT Trial, AVIM Thera...
Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
BACKBEAT Global Pivotal Trial evaluating AVIM Therapy completed enrollment and exceeded enrollment target, with a total of 349 patients randomized. BACKBEAT Trial primary endpoint data planned to be s...
Orchestra BioMed Holdings Quarterly report: Q3 2026
Orchestra BioMed Holdings has published its Q3 2026 quarterly earnings report on November 10, 2026.
Orchestra BioMed Holdings Earnings release: Q3 2026
Orchestra BioMed Holdings released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
Orchestra BioMed Announces Pricing of Public Offering
NEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technolo...
Orchestra BioMed announces common stock offering, no amount given
Orchestra BioMed (OBIO) Holdings announced that it has commenced an underwritten public offering of shares of its common stock. All of the securities are being offered by the company. The…
Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026
Presentation will highlight Virtue SAB's fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel wall. ...
Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
NEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...
Orchestra BioMed surpasses full enrollment in BACKBEAT trial
Orchestra BioMed (OBIO) announced that it has surpassed full enrollment in the BACKBEAT Global Pivotal Trial, exceeding its previously announced target of 316 randomized patients. The BACKBEAT Trial i...
Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
330 patients randomized as of September 30, 2026, surpassing full trial enrollment target Company reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consid...
OBIO's Capital Access Advisory Program (CAAP®) Reaches Milestone with $1 Billion Raised by High-Growth Life Sciences and Health Tech Ventures
TORONTO--(BUSINESS WIRE)--OBIO® companies supported through its Capital Access Advisory Program have now collectively raised over $1 billion in capital.
Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026
NEW HOPE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to pa...
Orchestra BioMed receives $6.1M milestone payment from Haemonetics
Orchestra BioMed (OBIO) announced the receipt of $6.1M as the first milestone payment in connection with the previously announced acquisition of Vivasure Medical by Haemonetics (HAE). This second paym...
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million Company remains eligible for up to approximately $10 million in ad...
Orchestra BioMed price target raised to $11 from $10 at B. Riley
B. Riley raised the firm’s price target on Orchestra BioMed (OBIO) to $11 from $10 and keeps a Buy rating on the shares after assuming coverage of the name. Orchestra…
Orchestra BioMed Holdings Transcript: Wells Fargo 21st Annual Healthcare Conference
The presentation highlighted a partnership-driven model advancing two pivotal-stage programs: AVIM therapy for hypertension in pacemaker patients and Virtue SAB for coronary artery disease. Both programs target large, established markets, are supported by major strategic partners, and are on track for key clinical and regulatory milestones.
Orchestra BioMed upgraded to Buy from Neutral at BTIG
BTIG analyst Marie Thibault upgraded Orchestra BioMed (OBIO) to Buy from Neutral with a $10 price target The firm is “more constructive” on the stock following recent management commentary detailing…
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HOPE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pa...
Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
NEW HOPE, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...
Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
NEW HOPE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...
Orchestra BioMed price target raised to $10 from $9 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on Orchestra BioMed (OBIO) to $10 from $9 and keeps an Overweight rating on the shares following quarterly results and…